

Korea's Seegene unveils world's first commercialised '3 Ct' PCR assay

27 April 2022 | News

'3 Ct' to lay foundation for automated syndromic testing and make MDx more accessible



Seegene Inc., South Korea's leading molecular diagnostics (MDx) company, has announced the development of the world's first commercialised PCR assay applying '3 Ct' technology.

The 'Allplex™ HPV HR Detection' was showcased at the 2022 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) held April 23-26 in Lisbon, Portugal.

In a polymerase chain reaction (PCR), the cycle threshold (Ct) value is used to quantify the concentration of a viral DNA sequence (the target). Due to technological limitations, the conventional real-time PCR technique finds the Ct value of one target in one channel.

But Seegene's '3 Ct' technology can provide the Ct value of three targets in one channel without compromising sensitivity and specificity. The successful development is based on Seegene's 20-year expertise and combines 19 different patented technologies, including DPO™, TOCE™, and MuDT™. Using five channels in a single tube, Seegene can provide quantitative data for a total of 15 targets. '3 Ct' has been dubbed the "dream MDx technology."

The company plans to apply '3 Ct' technology to its entire product line-up, including respiratory virus (RV), sexually transmitted infection (STI), gastrointestinal infection (GI), and urinary tract infection (UTI) assays. Seegene expects '3 Ct' technology to take syndromic testing to another level.